WANY
INBX icon

Wealthspire Advisors (New York)’s Inhibrx INBX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250
Closed -$8.42K – 1926
2025
Q3 		$8.42K Buy
+250
New +$6.16K ﹤0.01% 2105

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wealthspire Advisors (New York)'s INBX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Inhibrx (INBX) in Q4 2025, closing a stake of 250 shares — an estimated $8.42K sold.

Wealthspire Advisors (New York) first reported a position in INBX in Q3 2025 and held it in 1 quarter. The position peaked at $8.42K in Q3 2025. 138 funds tracked by Wall St. Rank hold INBX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Inhibrx position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 250 Inhibrx shares in Q4 2025, an estimated $8.42K.
  • Wealthspire Advisors (New York) first reported a position in Inhibrx in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Inhibrx position peaked at $8.42K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held Inhibrx as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.